BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker Corporation (NASDAQ: BRKR) today announced that on May 19, 2015,
Mr. Charles F. Wagner, Jr., Executive Vice President and the Chief
Financial Officer (CFO) of Bruker since July 2012, submitted his
resignation, effective June 12, 2015, in order to pursue other
interests. Mr. Wagner has informed the Company that he has accepted a
position as Chief Financial Officer of Ortho-Clinical Diagnostics, Inc.,
and will commence service in that position in late June 2015. Mr.
Wagner’s resignation is not the result of any dispute or disagreement
with the Company or any matter relating to the Company’s accounting
practices or financial statements.
Frank Laukien, Bruker’s President & CEO, commented, “I would like to
thank Charlie Wagner for doing an outstanding job as our Chief Financial
Officer over the last 3 years, and for his previous contributions to
Bruker as a director. Charlie has been a key architect of our Innovation
& Transformation strategy, and has helped Bruker strengthen its
leadership, processes and systems. While our transformation is
substantially planned and well underway, more work remains to be done,
as Bruker is committed to becoming a great company. I am grateful for
Charlie’s positive impact on Bruker, and wish him continued success in
his new role.”
Mr. Wagner said, “I am very proud of my five year affiliation with
Bruker, including two years on the Board of Directors and three years as
CFO. During that time, we have worked very hard to build upon Bruker’s
outstanding legacy and transform the company for the better. Bruker is a
stronger company today, because of those efforts.”
Mr. Wagner is expected to continue in his role as Bruker’s Chief
Financial Officer until his departure from the Company, and he will work
during the next few weeks to ensure an orderly transition of his
responsibilities. Bruker intends to initiate a search and until such
time as a new CFO is appointed, Mr. Anthony L. Mattacchione, an
executive officer and the Company’s Senior Vice President of Finance &
Accounting, will serve as interim CFO, effective upon Mr. Wagner’s
departure. Mr. Mattacchione joined the Company in February 2013, and is
currently responsible for the Company's global finance and accounting
functions, including corporate accounting, financial planning &
analysis, treasury, tax, shared financial services, internal controls
and internal audit. Prior to joining the Company, Mr. Mattacchione
served as Chief Financial Officer of EMD Millipore Corporation, a
subsidiary of Merck KGaA, and as Vice President, Controller and Chief
Accounting Officer of Millipore Corporation.
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance scientific research
instruments and high-value analytical solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science molecular
research, in applied and pharma applications, and in microscopy,
nano-analysis and industrial applications, as well as in cell biology,
preclinical imaging, clinical research, microbiology and molecular
diagnostics. For more information, please visit: http://www.bruker.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150520006393/en/
Source: Bruker Corporation